Ulcerative colitis (UC) is an inflammatory bowel disease characterized by a chronic intestinal inflammation due to dysregulated mucosal immune responses. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can lead to symptomatic improvement in various autoimmune diseases by resetting the immune system.
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There is a growing interest in the utility of allogeneic transplants in refractory inflammatory bowel disease (IBD), including UC. 2 However, due to high morbidity and mortality, allo-HSCT is currently not an accepted therapy of choice for severe steroidrefractory UC.
The efficacy of high-dose chemotherapy and pulse doses of cyclophosphamide (Cy) followed by autologous hematopoietic stem cell transplantation (ASCT) in IBD patients is well established. [3] [4] [5] [6] [7] [8] The benefit of allo-HSCT from HLA-matched donors in IBD patients, particularly for patients with Crohn's disease, has also been described. 9 However, little information is available about the efficacy of HLA-mismatched allo-HSCT and post post-transplantation Cy in patients with severe UC. Here we present a patient with severe UC who achieved a long-lasting remission after haploidentical HSCT (haplo-HSCT) followed by post-transplantation Cy.
The patient is a 44-year-old with a long history of severe UC, confirmed by endoscopic and histologic findings. He continued having a poorly controlled disease with frequent flares despite therapy with azathioprine, mercaptopurine, mesalamine, methotrexate, infliximab, high doses of steroids and adalimumab. Serial endoscopies showed persistent severe inflammation and ulcerations from the rectum to the mid-transverse colon (Figures 1a and b) .
He developed high-risk AML 5 years after the diagnosis of UC for which he received induction chemotherapy with idarubicin and cytarabine followed by two cycles of high-dose cytarabine consolidation. There was no worsening of UC symptoms during chemotherapy. Then, he received allo-HSCT from a haploidentical brother with busulfan plus fludarabine reduced-intensity conditioning followed by high-dose Cy on days 3 and 4 after transplant. He subsequently received mycophenolate mofitil for 4 weeks and tacrolimus for 6 months after haplo-HSCT. At HSCT, symptoms consistent with poorly controlled UC persisted but no increase in intestinal toxicity or clinical exacerbation of UC were observed during the conditioning and early post-transplant recovery. All immunosuppression was stopped at 6 months after haplo-HSCT without any signs of either acute or chronic GvHD or UC flares.
Complete regression of colonic inflammation after haplo-HSCT was confirmed by colonoscopy and resolution of clinical symptoms. Endoscopy and intestinal biopsy performed at 12 months after haplo-HSCT revealed only minor nonspecific chronic inflammation. At 24 months after haplo-HSCT he reported complete resolution of any UC-related symptoms, and endoscopy showed complete endoscopic healing of the mucosal lesions (Figures 2a and b) . At 4 years' post HSCT he is asymptomatic from his UC on low-dose mesalamine without any immunosuppression and maintains 100% donor chimerism.
Allo-HSCT is currently not a therapy of choice for severe steroidrefractory UC due to its high morbidity and mortality. However, because of potent immunomodulatory activity, there is a growing interest in the utility of allo-HSCT in steroid-refractory IBD. Use of high doses of Cy after allo-HSCT may add additional clinical benefit to these patients. Barta et al. 3 demonstrated the potential efficacy of pulsed-dose Cy in a small cohort of IBD patients, probably due to its suppressive effects on the autoreactive T cells. In allo-HSCT, the post-transplant high-dose Cy might be playing a key role in resetting the malfunctioning immune system and alleviating immune dysregulation leading to IBD. By analogy, in ASCT setting the high-dose chemotherapy causing lymphoblation Figure 1. (a, b) Severe UC prior to haplo-HSCT.
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2 reported a case series of 11 patients with hematologic malignancies and concurrent IBD (four patients with UC) who underwent allo-HSCT with post-transplant Cy, and achieved remission of their IBD. However, only one out of eight received allo-HSCT from a mismatched unrelated donor. They had one death, which was due to transplant-related complications. Ozgur et al. 11 reported an infant with SCID syndrome and IBD who was treated with a matched related donor allo-HSCT and had CR of the IBD after the transplant. Rabian et al.
12 studied 18 patients with IBD of which five patients had UC who received allo-HSCT for hematologic malignancy with only two patients had relapsed IBD after the transplant. None of these patients received a haplo-HSCT transplant. This study also demonstrated that IBD did not significantly increase the incidence of GvHD and should not be a contraindication for allogeneic transplant. 12 To summarize, allo-HSCT can help to achieve an immune reset and eliminate the autoreactive T-cell clones. These events can alter the natural history of severe steroid-refractory UC and lead to a cure. The post-transplant Cy may add a substantial benefit in the elimination of residual autoreactive host T cells, which would increase the chance of durable remission or cure of previously poorly controlled UC. In our patient, even after the withdrawal of all the immunosuppression there were no signs of recurrent UC, which supports the theory of immune reset and long-lasting disease control after haplo-HSCT with post-transplant Cy. 3, 8, 11 Additional benefits of haplo-HSCT include very low transplantrelated morbidity, mortality and almost universal donor availability. 13 This makes haplo-HSCT as a therapeutic option available for the vast majority of patients with severe UC who have exhausted all other therapeutic options. Further prospective studies are necessary to determine if haplo-HSCT might become a curative and clinically feasible option for patients with severe and refractory UC. Letter to the Editor
